Besides predicting responsiveness to anti-HER2 agents, HER2 aberrations are associated with a high incidence of central nervous system (CNS) metastasis across several cancer types, including breast, lung, gastric and colorectal cancer. In this setting, several novel anti-HER2 agents with relevant CNS activity are emerging, including tucatinib and trastuzumab deruxtecan. Both agents are already FDA-approved for treating advanced breast cancer, but are also being tested for the treatment of other HER2-driven histologies. The confirmation of their activity in other cancer types may provide histology-agnostic weapons against HER2-driven brain metastasis, possibly improving the prognosis of a wide population of cancer patients.
New anti-HER2 agents for brain metastasis: histology-agnostic weapons? / P. Tarantino, A. Prat, G. Curigliano. - In: BREAST CANCER RESEARCH AND TREATMENT. - ISSN 0167-6806. - 185:3(2021), pp. 879-881. [10.1007/s10549-020-05982-y]
New anti-HER2 agents for brain metastasis: histology-agnostic weapons?
G. Curigliano
Conceptualization
2021
Abstract
Besides predicting responsiveness to anti-HER2 agents, HER2 aberrations are associated with a high incidence of central nervous system (CNS) metastasis across several cancer types, including breast, lung, gastric and colorectal cancer. In this setting, several novel anti-HER2 agents with relevant CNS activity are emerging, including tucatinib and trastuzumab deruxtecan. Both agents are already FDA-approved for treating advanced breast cancer, but are also being tested for the treatment of other HER2-driven histologies. The confirmation of their activity in other cancer types may provide histology-agnostic weapons against HER2-driven brain metastasis, possibly improving the prognosis of a wide population of cancer patients.| File | Dimensione | Formato | |
|---|---|---|---|
|
Tarantino2021_Article_NewAnti-HER2AgentsForBrainMeta.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
343.23 kB
Formato
Adobe PDF
|
343.23 kB | Adobe PDF | [it] Default value: Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in AIR sono rilasciati con licenza CCO mentre i file delle pubblicazioni sono rilasciati con licenza CC BY-SA, salvo diversa indicazione. In caso di violazione di copyright, contattare l'assistenza di AIR




